HR 5782
115th Congress
House
Health
Business ethics
Business expenses
Business records
Child health
Civil actions and liability
Corporate finance and management
Department of Health and Human Services
Department of Justice
Department of Labor
Drug safety, medical device, and laboratory regulation
Drug trafficking and controlled substances
Drug, alcohol, tobacco use
Education programs funding
Elementary and secondary education
Employment taxes
Executive agency funding and structure
Government information and archives
Government studies and investigations
Government trust funds
Opioid Crisis Accountability Act of 2018
Introduced: May 11, 2018
See on congress.gov
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 31, 2018
Referred to the Subcommittee on Health.
May 11, 2018
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and the Workforce, Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
May 11, 2018
Introduced in House
Plain-English summary
Opioid Crisis Accountability Act of 2018
This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit a drug manufacturer from engaging in illegal marketing and distribution practices, including falsely advertising, promoting, or marketing that an opioid has no addiction-forming or addiction-sustaining qualities or risks, supplying states or communities with a quantity of opioids that is not medically necessary, or failing to report any order or pattern of orders that would cause a reasonable person to believe the opioids were not being dispensed in a medically reasonable manner.
What's happening now
Referred to the Subcommittee on Health.
Committees of jurisdiction
5